Author:
Shu Zun-Peng,Xia Tian-Yi,Wang Yi,Yang Yan-Ni,Wang Wu-Jing,Ding Zi-He,Zhong Ren-Xing,Chen Ying,Li Wei,Peng Ming-Ming,Li Chuan-Qiu,Shang Li-Feng,Liu Bing,Wang Zhen-Yue,Shi Chong-Rong
Subject
Complementary and alternative medicine
Reference26 articles.
1. Committee of Chinese Pharmacopoeia. Chinese pharmacopoeia (1sted.); Beijing: Medical Science and Technology Press; 2020.
2. Li AL, Chen BJ, Li GH, Zhou MX, Li YR, Ren DM, et al. Physalis alkekengi L. var. franchetii (Mast.) Makino: An ethnomedical, phytochemical and pharmacological review. J Ethnopharmacol 2018;210:260-74.
3. Physalin A induces G2/M phase cell cycle arrest in human non-small cell lung cancer cells: involvement of the p38 MAPK/ROS pathway;Kang;Mol Cell Biochem,2016
4. Yang Y, Ding Z, Wang Y, Zhong R, Feng Y, Xia T, et al. Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury. J Cell Mol Med 2020;24:5039-56.
5. Polysaccharides from fruit calyx of Physalis alkekengi var.francheti: Isolation, purification, structural features and antioxidant activities;Ge;Carbohydr Polym,2009